| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/29/2007 | US7223556 Targeted proteolysis by recruitment to ubiquitin protein ligases |
| 05/29/2007 | US7223440 Residual solvent extraction method and microparticles produced thereby |
| 05/29/2007 | US7223421 Teste masked pharmaceutical particles |
| 05/29/2007 | US7223419 Stabilizing a high concentrate drug content in water, by dissolving the drug and a polyetheramide copolymer in solvent, forming water in oil emulsion, volatilizing, desolventizing, supersonic treatment and ultrafiltration |
| 05/29/2007 | US7223417 Nutrient formulations |
| 05/29/2007 | US7223397 Administering an agent which upregulates the expression of a cellular target; administering a dose of an immunotoxin directed against the upregulated cellular target |
| 05/29/2007 | US7223393 Monoclonal antibodies for use in the prevention and treatment of cell proliferative and skin disorders; immunotherapy; antitumor agents |
| 05/29/2007 | US7223388 Reoviridae virus is conjugated to a hydroxylated hydrocarbon or a polycationic polymer to reduce the clearance and immunogenicity; antiproliferative disorders |
| 05/29/2007 | US7223387 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester |
| 05/29/2007 | US7223386 comprising silicone matrix, a hydrophilic carrier, and at least one active agent comprising proteins, particularly enzymes such as hydrolases and glucose oxidase for enzymatic debridement, clotting formation and clot removal and wound healing |
| 05/29/2007 | US7223381 Pressurised metered dose inhalers (MDI) |
| 05/29/2007 | CA2401718C Compositions and methods for treating hair loss using c16 - c20 aromatic tetrahydro prostaglandins |
| 05/29/2007 | CA2340052C Pharmaceutical compositions containing lipase inhibitors and chitosan |
| 05/29/2007 | CA2338324C Stabilized carvedilol injection solution |
| 05/29/2007 | CA2336732C Topical plaster with non-steroidal antirheumatic agents with an acid group |
| 05/29/2007 | CA2283852C Method and composition for coating wound or protecting animal skin |
| 05/29/2007 | CA2275420C Stable liquid mineral ascorbate compositions and methods of manufacture and use |
| 05/29/2007 | CA2268156C Bioceramic compositions |
| 05/29/2007 | CA2258679C Solid solution of an antifungal agent with enhanced bioavailability |
| 05/29/2007 | CA2251297C Oral preparations comprising s-(3-hydroxypropyl)-l-cysteine |
| 05/29/2007 | CA2247467C Use of piperine as a bioavailability enhancer |
| 05/29/2007 | CA2230952C The purification of alkoxylated fats |
| 05/29/2007 | CA2173317C Pharmaceutically acceptable polymeric tissue coating |
| 05/24/2007 | WO2007059507A2 Compositions comprising lipoxygenase inhibitors and cyclodextrin |
| 05/24/2007 | WO2007059404A2 Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| 05/24/2007 | WO2007059115A1 Anti-sepsis conjugate vaccine |
| 05/24/2007 | WO2007058935A2 Ophthalmic composition for dry eye therapy |
| 05/24/2007 | WO2007058190A1 Controlled drug release composition and drug releasing medical device |
| 05/24/2007 | WO2007057924A1 Laxative composition on the basis of triphala |
| 05/24/2007 | WO2007057583A1 Cosmetic and pharmaceutical compositions comprising lauroyl proline and an ester of anhydrohexitol and of an aliphatic carboxylic acid |
| 05/24/2007 | WO2007057582A1 Composition comprising a colloidal synthetic bioresorbable vector and a viral vector |
| 05/24/2007 | WO2007057182A2 Fluorescent nanoparticles |
| 05/24/2007 | WO2007057005A1 Lipopeptide compositions |
| 05/24/2007 | WO2007056861A1 Sirna silencing of influenza virus gene expression |
| 05/24/2007 | WO2007041206A3 Drug delivery nanocarriers targeted by landscape phage |
| 05/24/2007 | WO2007020195A3 Peg-ifn alpha and ribavirin for hbv treatment |
| 05/24/2007 | WO2007017291A3 Production of an oxaliplatin mixture and a container and a container set for said mixture |
| 05/24/2007 | WO2007016562A9 Formulations that inhibit protein aggregation |
| 05/24/2007 | WO2007016352A3 Oral liquid losartan compositions |
| 05/24/2007 | WO2007016018A3 Improved botulinum toxin compositions |
| 05/24/2007 | WO2006135506A3 Compositions for topical enzymatic debridement |
| 05/24/2007 | WO2006116302A3 High-potency botulinum toxin formulations |
| 05/24/2007 | WO2006095345A3 Targeted drug-carrying bacteriophages |
| 05/24/2007 | WO2006055632A3 Pharmaceutical manufacturing process for heat sterilized glucocorticoid suspensions |
| 05/24/2007 | WO2006045796A9 Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof |
| 05/24/2007 | WO2006035431A3 Fatty acid modified polylysines as antimicrobial agents |
| 05/24/2007 | WO2006029089A3 Tetrahydrocannabinoid- protein conjugates for the production of antibodies for the detection of tεtrahydrocannabinoid components in saliva |
| 05/24/2007 | WO2005117842A3 Decontaminant edible product, methods of production and uses thereof |
| 05/24/2007 | WO2005012484A3 Antibody-toxin conjugates |
| 05/24/2007 | WO2004087071A3 Use of benzyl alcohol, and other phenolic preservatives to reduce pain during intradermal injection |
| 05/24/2007 | US20070117959 Novel polyesters |
| 05/24/2007 | US20070117924 Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same |
| 05/24/2007 | US20070117783 Aqueous suspensions of ciclesonide for nebulisation |
| 05/24/2007 | US20070117758 Treating treating angiogenic disease, e.g., cancer, by administering therapeutically effective amount of compounds of the invention, for example, {(3R, 4S, 5S, 6R)-5-Methoxy-4-[(2R, 3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino}-3-methyl-butyric acid methyl ester |
| 05/24/2007 | US20070117129 Antigen arrays for treatment of bone disease |
| 05/24/2007 | US20070116768 Sustained release preparations composed of biocompatible complex microparticles |
| 05/24/2007 | US20070116764 Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing |
| 05/24/2007 | US20070116731 Dermatological cream-gels containing avermectin compounds |
| 05/24/2007 | US20070116723 Topically applied clostridium botulinum toxin compositions and treatment methods |
| 05/24/2007 | US20070116700 For subcutaneous administration; hypertonic; useful for preventing self-association of reconstituted lyophilized formulations |
| 05/24/2007 | US20070116667 Colon cleansing compositions and methods |
| 05/24/2007 | US20070116654 Cosmetics |
| 05/24/2007 | US20070116644 Detectable labeled cobalamin (adenosylcolbalamin) conjugated with peptidesor amino acid residues linked to a chelate compound (ETDA) including a metal radionuclide;antitumor, anticarcinogenic agents; contrast agent for imaging; diagnosis; nontoxic;bioavailability; detectable at low concentrations |
| 05/24/2007 | DE20321455U1 Stabilisiertes pharmazeutisches Erzeugnis, das einen amorphen Wirkstoff enthält A stabilized pharmaceutical product which contains an amorphous active ingredient |
| 05/24/2007 | DE102005055576A1 Rotes Effektpigment und dessen Verwendung in der Kosmetik und im Lebensmittel- und Pharmabereich Red effect pigment and its use in cosmetics and in food and pharmaceutical industries |
| 05/24/2007 | CA2630530A1 Composition comprising a colloidal synthetic bioresorbable vector and a viral vector |
| 05/24/2007 | CA2630497A1 Lipopeptide compositions |
| 05/24/2007 | CA2630193A1 Pharmaceutical composition free from dexpanthenol, calcium ions, and phosphate, and use of calcium chelating agent and ophthalmologically compatible viscosity regulator |
| 05/24/2007 | CA2627190A1 Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| 05/24/2007 | CA2626778A1 Angiogenesis-promoting substrate |
| 05/24/2007 | CA2626122A1 Compositions comprising lipoxygenase inhibitors and cyclodextrin |
| 05/23/2007 | EP1788082A1 Nucleic acid construct |
| 05/23/2007 | EP1787993A1 Crystalline maltitol powder less prone to consolidation and method for production thereof |
| 05/23/2007 | EP1787970A1 Method of obtaining polyphenolic extracts from cocoa beans, the extracts obtained and their applications |
| 05/23/2007 | EP1787661A1 Medicinal preparation |
| 05/23/2007 | EP1787660A1 New adjuvants on the basis of bisacyloxypropylcysteine conjugates and their uses in pharmaceutical compositions |
| 05/23/2007 | EP1787659A1 Fluorescent nanoparticles |
| 05/23/2007 | EP1787658A1 Sustained release formulations of somatostatin analogue inhibitors of growth hormone |
| 05/23/2007 | EP1787643A1 Implants and microspheres for the sustained release of drugs for ophthalmic use and preparation methods thereof |
| 05/23/2007 | EP1787640A1 Time-limited release type granular pharmaceutical composition for oral administration and intraoral rapid disintegration tablet containing the composition |
| 05/23/2007 | EP1787639A2 Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
| 05/23/2007 | EP1786841A1 Ultrasound-assisted synthesis of cyclodextrin-based nanosponges |
| 05/23/2007 | EP1786469A2 Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates |
| 05/23/2007 | EP1786468A1 Composition for promoting vascular smooth muscle relaxation |
| 05/23/2007 | EP1786467A1 Method of enhancing absorptions of transmucosal administration formulations |
| 05/23/2007 | EP1786459A2 Therapeutic composition whit a botulinum neurotoxin |
| 05/23/2007 | EP1786406A1 Skin coating composition and uses thereof |
| 05/23/2007 | EP1786400A2 Pharmaceutical compositions for controlled release delivery of biologically active compounds |
| 05/23/2007 | EP1786399A2 A suspension comprising an active principle, a suspending vehicle, a density-modifying solid with an increased physical stability |
| 05/23/2007 | EP1786398A1 Testosterone gels comprising propylene glycol as penetration enhancer |
| 05/23/2007 | EP1786397A1 Phenytoin formulations, and uses thereof in wound healing |
| 05/23/2007 | EP1786395A1 Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b and other therapeutic proteins |
| 05/23/2007 | EP1554936B1 Ketoprofen-supplemented animal feed and use thereof in the simultaneous treatment of a group of animals for processes which are accompanied by fever, inflammation and/or pain |
| 05/23/2007 | EP1480679B1 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
| 05/23/2007 | EP1478344B1 Melt extrusion consisting of salts of active ingredients |
| 05/23/2007 | EP1442066B1 Compositions comprising chitosan in the form of nano-sized fibres |
| 05/23/2007 | EP1427447A4 Improved therapeutic protocols |
| 05/23/2007 | EP1379575B1 Composition for soluble films with a new hydrolyzed polysaccharide |
| 05/23/2007 | EP1332170B1 Method for producing microspherical crystallites from linear polysaccharides, corresponding microspherical crystallites and the use thereof |
| 05/23/2007 | EP1140203B1 Vitronectin receptor antagonist pharmaceuticals |